Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Cannabinoids and pain / / Samer N. Narouze, editor
| Cannabinoids and pain / / Samer N. Narouze, editor |
| Pubbl/distr/stampa | Cham, Switzerland : , : Springer, , [2021] |
| Descrizione fisica | 1 online resource (xix, 339 pages) : illustrations (black and white) |
| Disciplina | 615.7827 |
| Soggetto topico |
Cannabinoids - Therapeutic use
Pain - Chemotherapy Cànnabis Ús terapèutic |
| Soggetto genere / forma | Llibres electrònics |
| ISBN |
9783030691868
3-030-69186-1 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Part I: Introduction to Cannabis -- 1: History of Cannabis -- 2: Cannabis Regulations -- Introduction -- Federal Regulations -- State Cannabis Laws -- Research Expansion -- Conclusion -- 3: The Demand for Medical Cannabis Education -- 4: Pain Physicians and Medical Cannabis: Attitudes, Believes, Preparedness and Knowledge -- Introduction -- Development and Description of the Applied Questionnaire -- Statistical Analysis -- Results -- Discussion -- Summary -- Medical Cannabis Questionnaire -- 5: Cannabis Terminology -- Introduction -- General Aspects of the Cannabis Plant -- Differences Between C. sativa and C. indica -- Cannabis Versus Hemp -- The Endocannabinoid System (ECS) -- Key Terminology -- Cannabis Products and Accessories -- Conclusion -- Part II: Cannabinoids Pharmacology -- 6: The Endocannabinoid System -- Introduction -- Brief History of Cannabis and Hemp -- Components of the Endocannabinoid System (ECS) -- eCBs and Their Signal Transduction Pathways -- Complexity of the Endogenous Cannabinoid System -- CB1 and CB2 Receptor -- Other Receptors -- Transporters -- Enzymes -- Physiological Actions of ECS -- 7: Cannabinoid Receptor 1 (CB1) -- CB1 Receptors -- CB1 Receptor Physiology, Pathology, and Pharmacology -- CB1 Signaling -- CB1 Receptor Distribution -- Neocortex -- Hippocampus -- Hypothalamic -- Midbrain Periaqueductal Gray -- Brain Stem Rostral Ventromedial Medulla -- Tolerance -- CB1 Receptor Ligands -- References -- 8: Cannabinoid Receptor 2 (CB2) -- Cannabinoid 2 Receptor -- CB2 Receptor Physiology and Pharmacology -- CB2 Receptor Distribution -- CB2 Signaling -- CB2 Chronic Pain Models -- Tolerance -- CB2 Receptor Ligands.
9: Endocannabinoids: Anandamide and 2-Arachidonoylglycerol (2-AG) -- Introduction -- Biosynthesis and Breakdown Pathways -- Anandamide -- 2-AG -- Endocannabinoids' Mechanism of Action -- Anandamide -- 2-AG -- Plasticity of Endocannabinoid Signaling -- Endocannabinoids in Pain -- Peripheral Mechanisms -- Spinal Mechanisms -- Supraspinal Mechanisms -- Conclusion -- 10: Phytocannabinoids: Tetrahydrocannabinol (THC) -- Phytocannabinoids -- Introduction -- Δ9-Tetrahydrocannabinol (THC) -- Mechanism of Action of THC -- Applied Pharmacology and Pharmacokinetics -- Absorption -- Smoking -- Oral -- Oro-mucosal and Intranasal -- Rectal -- Transcutaneous -- Distribution -- Metabolism and Elimination -- Conclusion -- 11: Phytocannabinoids: Cannabidiol (CBD) -- Phytocannabinoids -- Cannabidiol and Its Various Clinical Effects -- Pharmacodynamics of Cannabidiol -- Applied Pharmacology and Pharmacokinetics -- Smoking -- Oral -- Transcutaneous -- Volume of Distribution -- Metabolism -- Elimination -- Safety Profile and Side Effects -- Cannabidiol Interaction with Tetrahydrocannabinol -- Conclusion -- 12: Other Phytocannabinoids -- Introduction -- Synthesis of Phytocannabinoids -- Cannabinoids and the Endocannabinoid System (ECS) -- Minor Cannabinoids -- Cannabinol (CBN) -- Cannabigerol (CBG) -- Cannabichromene (CBC) -- Tetrahydrocannabivarin (THCV) -- Conclusion -- 13: Cannabis Drug Interactions -- Introduction -- Routes of Administration -- Cannabinoid Drug Interactions -- Specific Drug Interactions -- Over-the-Counter (OTC) Analgesics -- Neuropathic Agents -- Opiates -- Antiepileptics -- Psychotropics -- Anticoagulants and Antiplatelets: "Blood Thinners" -- Warfarin -- Direct Oral Anticoagulants -- Clopidogrel -- Heparin/Fondaparinux -- References -- Part III: Pharmaceutical Cannabinoids. 14: Dronabinol (Marinol®) -- Introduction -- Mechanism of Action -- Pharmacokinetics -- Therapeutic Use -- Safety, Toxicity, and Adverse Effects -- 15: Nabilone (Cesamet) -- Introduction -- Clinical Trials -- Pharmacology and Pharmacokinetics -- Dosage and Administration -- Monitoring, Adverse Events, Drug Interactions, and Abuse Potential -- Adverse Effects -- Drug Interactions -- Abuse Potential -- 16: Cannabidiol (Epidiolex) -- Introduction -- Clinical Trials -- Pharmacology and Pharmacokinetics -- Dosage and Administration -- Monitoring, Adverse Events, and Drug Interactions -- Adverse Effects -- Abuse Potential -- 17: Nabiximols (Sativex®) -- Introduction -- Nabiximols Production -- Nabiximols Approval and Indications -- Nabiximols Contraindication -- Nabiximols Evidence -- Nabiximols for MS-Related Spasticity -- Nabiximols for MS-Related Neuropathic Pain -- Nabiximols for Cancer-Related Pain -- Nabiximols for Chronic Pain -- Nabiximols Tolerability -- Nabiximols Dosage and Administration -- Administration -- Dosing -- Storage, Stability, and Dosage Form -- Storage and Stability -- Dosage Form -- Summary -- Part IV: Medical Cannabis -- 18: Cannabis Strains to Chemovars -- Introduction -- Cannabis sativa L. -- Cannabis Cultivation and Trichomes -- Importance of Trichomes -- Cannabis Constituents -- Cannabinoids -- Terpenoids -- Other Cannabis Compounds -- Entourage Effect of Cannabis Constituents -- Cannabis Classification: Strains Versus Chemovars -- Strains -- Chemovar -- Practical Chemovar Selection for Clinicians -- Summary -- 19: The Model of a Medical Cannabis Clinic -- Introduction -- Description of a Medical Cannabis Clinic -- Referral and Screening -- Initial Visit -- Follow-Up and Monitoring -- Patient Education and Physician Communication. Protocols and Procedure Guidelines -- Continuing Medical Education -- Research Development -- Conclusion -- References -- 20: Barriers for the Prescription of Cannabinoid-Based Medicines -- Introduction -- Barriers for Cannabinoid Prescription -- Social Stigma for the Use of Cannabis -- Myths Versus Realities of Medical Cannabis Use -- Research Gaps and Limitations to Justify Medical Cannabis Use -- Lack of Knowledge Regarding Cannabis Regulatory Frameworks -- Limited Medical Cannabis Education -- Development of Medical Cannabis Education Programs with High Scientific Content -- Conclusion -- 21: Practical Recommendations for the Use of Medical Cannabis -- Introduction -- Cannabinoid-Based Medicines: What Is Currently Available? -- Prescription or Pharmaceutical Cannabinoids -- Natural Cannabis -- Inhalation -- Practical Recommendations [11, 12] -- Oral Administration -- Practical Recommendations [11, 12] -- Therapeutic Properties of Cannabinoids: THC Versus CBD -- Practical Recommendations for the Prescription of Cannabinoid-Based Medicines -- Clinical Evidence to Support Cannabinoid Use in Specific Medical Conditions -- Is the Patient a Candidate for Cannabinoid Therapy? A Systematic Approach -- Conclusion -- 22: Cannabinoid-Based Medicines: Dosing, Titration & -- Monitoring -- Introduction -- Methods of Administration -- Inhalation: Smoking and Vaporizing -- Oral -- Oromucosal -- Topical -- Dosing -- Concentration and Potency -- Cannabis Flower Dosing -- Cannabis Oil Dosing -- Achieving Optimal Therapeutic Dose and Cannabis Rotation -- Cannabis Chemovar Rotation and Reduction -- Monitoring -- Summary -- 23: Cannabinoid-Based Medicines: Patient Safety Considerations -- Introduction -- Practical Considerations for Cannabis Use -- Considerations -- Immunocompromised Patients. Calcineurin Inhibitors, Protein Disulfide Isomerase (PD1) Inhibitors, and Biologics -- Chronic Kidney Disease -- Older Adults and Patients with Concurrent Medical Conditions -- Polypharmacy and Drug Interactions [10] -- Precautions -- Concurrent Active Mood or Anxiety Disorder -- Patients with Risk Factors for Cardiovascular Disease (CVD) -- Tobacco Use -- E-Cigarette Use -- Severe Liver Dysfunction or Disease -- Medications Associated with Sedation or Cognitive Impairment -- Driving and Safety Sensitive Occupations -- Relative Contraindications -- Individuals Under the Age of 25 -- Cannabis Use Disorder (CUD) -- Substance Use Disorder (SUD) and Consideration for Harm Reduction -- Contraindications -- Cardiovascular Disease -- Respiratory Disease -- Psychosis and Bipolar Disorders -- Pregnancy and Breastfeeding -- Summary -- Part V: Cannabinoids and Pain -- 24: Cannabinoids and Pain: Mechanisms of Action -- Introduction -- Endocannabinoids' Mechanism of Action -- Anandamide (AEA) -- 2-Arachidonoylglycerol (2-AG) -- Endocannabinoids and Pain Modulation -- Peripheral Mechanisms -- Spinal Mechanisms -- Supraspinal Mechanisms -- Anandamide and 2-AG Synergistic Effect -- Endocannabinoid Receptors -- CB1 Receptors -- Central CB1 Receptors -- Peripheral CB1 Receptors -- Central CB2 Receptors -- Peripheral CB2 Receptors -- Other Putative Endocannabinoid Receptors: TRPV1 and GPR55 -- TRPV1 -- GPR55 -- Phytocannabinoids (THC and CBD) -- THC -- CBD -- Mechanisms of Action in Pain Modulation -- THC -- CBD -- References -- 25: Cannabinoids and Pain: Clinical Evidence -- Introduction -- Chronic Non-cancer Pain -- Chronic Neuropathic Pain -- Fibromyalgia -- Rheumatoid Arthritis -- Cancer Pain -- Acute Nociceptive Pain -- Summary -- 26: Cannabinoids and Cancer Pain -- Introduction -- Relevant Mechanisms of Cancer Pain. Current Understanding of Clinical Studies. |
| Record Nr. | UNINA-9910488702303321 |
| Cham, Switzerland : , : Springer, , [2021] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Cannabis in medicine : an evidence-based approach / / edited by Kenneth Finn
| Cannabis in medicine : an evidence-based approach / / edited by Kenneth Finn |
| Edizione | [First edition.] |
| Pubbl/distr/stampa | Cham : , : Springer International Publishing : , : Imprint : Springer, , 2020 |
| Descrizione fisica | 1 online resource (xxxi, 554 pages) : 39 illustrations, 32 color illustrations |
| Disciplina | 615.7827 |
| Soggetto topico |
General practice (Medicine)
Primary care (Medicine) Pain medicine Cannabis - Theraputic use General Practice / Family Medicine Primary Care Medicine Pain Medicine Cànnabis Fitoteràpia Medicina basada en l'evidència |
| Soggetto genere / forma | Llibres electrònics |
| ISBN |
9783030459680
3-030-45968-3 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Forward: Losing Ground: The Rise of Cannabis Culture -- Part 1: Basic Science -- Chapter 1 The Properties and Use of Cannabis sativa Herb and Extracts -- Chapter 2 Cannabinoid and Marijuana Neurobiology -- Chapter 3 The Pharmacodynamics, Pharmacokinetics, and Potential Drug Interactions of Cannabinoids -- Part 2 Clinical Evidence -- Chapter 4 Cannabis and Neuropsychiatric Effects -- Chapter 4.1 Blunted: The Effects of Cannabis on Cognition and Motivation -- Chapter 4.2 Cannabis and Psychiatric Conditions -- Chapter 4.3 Cannabis use and psychosis, mood, and anxiety disorders -- Chapter 4.4 Marijuana and Suicide: Case-control Studies, Population Data, and Potential Neurochemical Mechanisms -- Chapter 4.5 Cannabis Use Disorder, Treatment, and Recovery -- Chapter 5 Cannabis and the Impact on the Pediatric and Adolescent Population -- Chapter 5.1 Cannabis and Young Pediatric Exposures -- Chapter 5.2 Cannabis and the Teen Brain -- Chapter 6 Acute Emergency Department Presentations Related to Cannabis -- Chapter 7 Evidence of Cannabinoids in Pain -- Chapter Cannabis in Pulmonary Medicine -- Chapter 8.1 Cannabinoids and the Respiratory System -- Chapter 8.2 THC and CBD Decomposition and Terpene Hazards While Vaping or Dabbing -- Chapter 9 Clinical Cardiovascular Effects of Cannabis Use -- Chapter 10 Cannabinoids in Neurologic Conditions -- Chapter 10.1 Cannabis and Cannabinoids for the Treatment of Epilepsy -- Chapter 10.2 Multiple Sclerosis and Cannabis - Benefits, Risks, and Special Considerations -- Chapter 10.3 Evidence for Cannabis in Movement Disorders -- Chapter 10.4 Cannabinoids in Neurosurgery -- Chapter 11 Ocular Conditions and the Endocannabinoid System -- Chapter 12 Cannabis in Oncology and Symptom Management -- Chapter 13 Cannabis in Palliative Medicine -- Chapter 14 Cannabis in Older Persons -- Chapter 15 Cannabinoids in Dermatology -- Chapter 16 Fetal and Neonatal Marijuana Exposure -- Chapter 17 Cannabinoids in Gastrointestinal Disorders -- Chapter 17.1 Investigation of Cannabinoid Hyperemesis Syndrome: pathophysiology, treatment, and burden -- Chapter 17.2 Investigation of the endocannabinoid system in the pathophysiology of irritable bowel syndrome and the potential use of cannabis as a complementary and alternative medicine therapy -- Chapter 17.3 Inflammatory Bowel Disease and Cannabis -- Chapter 17.4 Cannabis in relation to Gastroesophageal Reflux Disease -- Chapter 17.5 Nonalcoholic Fatty Liver Disease and Cannabinoids -- Chapter 18 Looking at Marijuana Through the Lens of Public Health -- Chapter 19 Cannabis-Impaired Driving: Evidence and the Role of Toxicology Testing -- Chapter 20 The Legal Aspects of Marijuana as Medicine -- Epilogue/Summary. |
| Record Nr. | UNINA-9910411944903321 |
| Cham : , : Springer International Publishing : , : Imprint : Springer, , 2020 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Cannabis/hemp for sustainable agriculture and materials / / edited by Dinesh Chandra Agrawal, Rajiv Kumar, Muralikrishnan Dhanasekaran
| Cannabis/hemp for sustainable agriculture and materials / / edited by Dinesh Chandra Agrawal, Rajiv Kumar, Muralikrishnan Dhanasekaran |
| Pubbl/distr/stampa | Singapore : , : Springer, , [2022] |
| Descrizione fisica | 1 online resource (335 pages) |
| Disciplina | 905 |
| Soggetto topico |
Cannabis
Cànem Cànnabis Aplicacions industrials |
| Soggetto genere / forma | Llibres electrònics |
| ISBN |
981-16-8778-1
981-16-8777-3 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910743254703321 |
| Singapore : , : Springer, , [2022] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Medicinal cannabis and CBD in mental heathcare / / Kylie O'Brien, Philip Blair
| Medicinal cannabis and CBD in mental heathcare / / Kylie O'Brien, Philip Blair |
| Autore | O'Brien Kylie |
| Pubbl/distr/stampa | Cham, Switzerland : , : Springer, , [2021] |
| Descrizione fisica | 1 online resource (xxi, 576 pages) |
| Disciplina | 615.7827 |
| Soggetto topico |
Cannabinoids - Therapeutic use
Mental illness - Treatment Cànnabis Ús terapèutic Malalties mentals |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 3-030-78559-9 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
1: Introduction -- Why This Book? -- The Structure of the Book -- Limitations -- Medicinal Cannabis as Part of a Holistic Therapeutic Approach -- Your Journey -- A Final Note from Dr. Blair -- References -- 2: Endocannabinoid System -- Introduction -- Purpose of the Endocannabinoid System -- Components of the Endocannabinoid System: Overview -- Endogenous Ligands: Endocannabinoids -- Endocannabinoids in Brief -- Synthesis of AEA and 2-AG -- Binding to Receptors (Extracellular and Intracellular) -- Transport Across the Plasma Membrane -- Intracellular Reservoirs Challenge Classic Understanding of Endocannabinoid On-Demand Synthesis -- Degradation of Endocannabinoids -- AEA Degradation -- 2-AG Degradation -- New Signaling Molecules Generated -- A Fine-Tuned Modulation System -- AEA and 2-AG in More Detail -- Anandamide (AEA) -- 2-Arachidonylglycerol (2-AG) -- Key Difference Between Endocannabinoids and Phytocannabinoids -- Endocannabinoid-Like Compounds: PEA, OEA, and Oleamide -- N-palmitoylethanolamide (PEA) and Oleoylethanolamide (OEA) -- Oleamide -- Cannabinoid Receptors -- Discovery of Cannabinoid Receptors -- Location of Cannabinoid Receptors -- Location of CB1 Receptors: Overview -- Neuroprotection -- CB1 Receptors in the CNS -- Glutamate and GABAergic Receptors -- CB1 Receptors Are More Abundant than Mu-Opioid Receptors -- CB1 Receptors and Cerebromicrovascular Endothelial Cells -- CB1 Receptors in Peripheral Nervous System and Periphery -- CB1 Receptors in the Peripheral Nervous System -- CB1 Receptors in the Gut -- CB1 Receptors in the Skin -- CB1 Receptors in the Liver -- Contrary Actions in the Periphery Compared with CNS: CB1 Receptors in Adipocytes -- Intracellular CB1 Receptors -- Different Isoforms of CB1 Receptors -- Functions of CB1 Receptors -- Functions of Mitochondrial CB1 Receptors.
CB2 Receptors -- CB2 Receptors and the Immune System -- CB2 Receptors in the Brain -- Unique Features of CB2 Receptors Compared with CB1 Receptors -- CB2 Receptors in Other Organs and Tissues -- CB2 Receptors in Skin -- Mechanisms of Action of the Endocannabinoid System (ECS) -- Classic Understanding of How the ECS Works in the Nervous System -- Complexity of the ECS: Multiple Signaling Pathway Involvement -- Biased Agonism -- Heteromers -- The ECS in Non-neural Cells -- ECS Signal Transmission Via Microvesicles -- Other Receptor Targets for Endocannabinoids -- TRPV1 Receptors -- Peroxisome Proliferator-Activated Receptors (PPARs) -- GPR55 Receptors -- The Endocannabinoid System in Neuroprotection -- Development and the Endocannabinoid System -- The ECS in Early Life -- The Adolescent Brain and the ECS -- Endocannabinoid System Dysfunction and Disease -- The Concepts of Endocannabinoid Tone and Endocannabinoid Deficiency -- Diseases in Which ECS Dysfunction Is Implicated -- Endocannabinoid System Dysfunction and Mental Health -- Omega 3 and 6 PUFAs in the Brain Health -- Diet and Importance of Omega 3 Fatty Acids for a Healthy ECS -- Studies Linking Omega 3 Deficiency and Mental Health Conditions -- Link Between ECS, Omega 3, and Omega 6 -- Why Are Omega 3 PUFAs Important for Functioning of the ECS? -- Why Are Dietary Sources of Long-Chain PUFAs Important? -- The Problem with the Western Diet -- Hemp Seeds Have a Very Good Ratio of Omega 6/Omega 3 PUFAs -- Conclusion -- References -- 3: The Endocannabinoid System, Stress, and Mental Health -- Introduction -- Key Brain Structures Involved in the Regulation of Stress -- Corticolimbic System -- Roles of the Components of the Corticolimbic System -- Hypothalamic-Pituitary-Adrenal (HPA) Axis -- Other Areas -- The Stress Response -- The Autonomic Stress Response. Sympathetic Nervous System Mechanisms of Action -- Parasympathetic Nervous System Neuroanatomical Connections -- Measurement of ANS Activity -- Neuroendocrine Stress Response -- The HPA Axis in Stress -- Measurement of Neuroendocrine Activity -- Sex Differences in the Stress Response System Along the HPA Axis -- When the Stress Response Becomes Pathological -- Stress and Inflammation -- How Does Stress Activate Inflammatory Changes? -- Endocannabinoid System and Stress Regulation -- Several Lines of Evidence that the ECS Is a Regulator of the Stress Response -- Bidirectional Relationship Between Stress and the ECS -- ECS and the Autonomic Nervous System Stress Response -- ECS, the Corticolimbic System, and the HPA Axis -- ECS and Regulation of the HPA Axis -- How Is the ECS Involved in Acute and Chronic Stress? -- Acute Stress -- Chronic Stress -- The Endocannabinoidome (Extended ECS) and Stress -- Genes, Stress, and the Endocannabinoid System -- Social Isolation -- Environmental Enrichment -- Early Life Stress and the Endocannabinoid System -- Early Life Stress, Corticolimbic System, and HPA Axis Development -- Stress Responsivity -- Findings from Animal Models -- Early Life Stress and Genetic Patterns in Humans -- Sex Differences in How Early Life Stress Affects the ECS -- The Gut and Stress -- The Gut Microbiome and Stress -- Microbiota Changes and Stress -- The Gut Regulates the HPA Axis -- Leaky Gut and Mental Health -- The Endocannabinoidome, the Gut, and Links to Mental Health -- Inflammation, the Gut, and the ECS -- Cannabis Exposure and Stress Responsivity -- Conclusion -- References -- 4: Overview of Medicinal Cannabis -- Introduction -- Definition of Medicinal Cannabis -- Taxonomy: What Is in a Name? -- Hemp -- Hemp Oil and Hemp Seed Oil -- Historical Use of Cannabis as Medicine -- Cannabis in China -- Cannabis in Other Ancient Cultures. Medicinal Cannabis in the Western World -- Regulations in the USA -- Active Constituents of Cannabis -- Where Are the Phytocannabinoids and Terpenes Found? -- Entourage Effect -- Cannabis Strains/Cultivars and Active Constituent Profiles -- Genes and Environmental Conditions -- A Word of Caution About Reductionism -- Phytocannabinoids: Overview -- Cannabidiol -- Therapeutic Actions of CBD -- What Conditions Can CBD Potentially Treat? -- Mechanisms of Action of CBD -- CBD Modulates Endocannabinoid Tone and Adenosine Tone -- CBD Modulates Multiple Signalling Systems -- Immunological and Anti-Inflammatory Effects -- Antioxidant Activity -- Anti-Bacterial Effect -- Cellular Benefits in the Central Nervous System -- Effects on Cardiovascular System -- Anti-Cancer Activity and Exosomes -- CBD Antagonism and Potentiation of THC -- Potentiation -- Antagonism -- Cannabidiolic Acid (CBDA) -- Tetrahydrocannabinol (THC) -- Therapeutic Actions of THC -- Mechanism of Action of THC -- Anti-Inflammatory Effects -- Anti-Ageing Effects -- THCA-A -- Other Phytocannabinoids -- Cannabichromene (CBC) -- Tetrahydrocannabivarin (THCV) -- Terpenes -- Actions of Terpenes -- Forms of Medicinal Cannabis -- Oils Are Not Oils -- A Gap in Our Knowledge: Lack of Studies in Whole Plant Extracts -- Superiority of Whole Spectrum CBD Over Pure CBD Isolate Demonstrated -- Dangers of Meta-Analyses -- Routes of Delivery and Pharmacokinetics -- Inhalation -- Oral Route -- Topical Route, Other Routes -- Bioavailability of CBD -- Bioavailability and Onset and Duration of Action of THC -- Safety -- Going Forward: The United Nations and the Single Convention -- Conclusion -- References -- 5: Anxiety -- Introduction -- Anxiety: Overview -- Types of Anxiety Disorder -- Associated Comorbidities -- Treatment of Anxiety -- Pathomechanisms Involved in Anxiety. Role of the Amygdala and Prefrontal Cortex in Anxiety -- Serotonin in Anxiety -- Noradrenergic System Involvement in Anxiety -- GABA Involvement in Anxiety -- Immune Dysfunction and Inflammation in Anxiety -- Inflammation and Anxiety -- Oxidative Stress -- Neurogenesis and the Hippocampus -- Adult Hippocampal Neurons and the Stress Response -- Neuritogenesis and Anxiety -- The Endocannabinoid System in Anxiety -- HPA Axis in Anxiety -- Endocannabinoids, Cannabinoid Receptors and Anxiety -- Enzymes of the ECS -- TRPV1 -- Scientific Evidence: CBD in the Treatment of Anxiety -- Mechanisms of Action of CBD in Anxiety -- CBD and the Serotonergic System -- CBD and the HPA -- CBD, Neurogenesis and Neuritogenesis -- CBD and Endocannabinoid Degradation -- CBD, Inflammation and Immune Function -- CBD, Sleep and Anxiety -- Animal Research: Efficacy of CBD in Anxiety -- Animal Models of Anxiety: Elevated Plus Maze -- Anxiety Studies in Rodents -- Animal Studies of Chronic CBD Administration -- Pure CBD Isolate and the Bell-Shaped Dose-Response Curve in Animal Studies -- Animal Study of Pure CBD Versus Whole Plant CBD -- Animal Research of CBDA in Anxiety -- Human Research: Efficacy of CBD in Anxiety -- Surveys -- Regional Cerebral Brain Flow Studies: Anxiety and CBD -- Observational Study: CBD and Anxiety -- Case Studies and Case Series -- Randomised Controlled Trials: CBD for Treatment of Anxiety -- Systematic Reviews: CBD and Anxiety Treatment -- Scientific Evidence: THC in the Treatment of Anxiety -- Preclinical Research: Effects of THC on Anxiety -- Anti-inflammatory Effects -- Human Research: Effects of Cannabis and THC on Anxiety -- Brain Imaging Studies -- Survey of Whole Plant Cannabis: Are Some Strains Better in Alleviating Anxiety? -- Observational Studies -- Randomised Controlled Trials -- Systematic Reviews. Does Adding CBD to THC Lower Its Anxiogenic Effect?. |
| Record Nr. | UNINA-9910508449403321 |
O'Brien Kylie
|
||
| Cham, Switzerland : , : Springer, , [2021] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
